NCT06806033
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
At risk: Primary completion moved 2 years 6 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 25 versions: 23 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 24 words
- Notable Primary completion pushed from Jan 31, 2027 to Jul 31, 2029
- Study completion pushed from Mar 30, 2029 to Jul 31, 2030
- Site details revised at 7 of 53 sites
- Notable Eligibility criteria expanded, about 41 words
- Secondary endpoints: details revised at 1 of 9 entries
- Site details revised at 5 of 53 sites
Notable Eligibility criteria expanded, about 119 wordsv22 Show 5 more changesShow less
- Enrollment increased: 100 → 130 participants
- Trial arms changed: 1 → 2
- Secondary endpoints: 8 to 9
- Primary endpoint revised
- Study title shortened, about 14 words
- Minor Site details revised at 2 of 53 sitesv21
Show 17 earlier versionsHide 17 earlier versions
- Minor Site details revised at 5 of 53 sitesv20
- Minor Site details revised at 2 of 53 sitesv19
- Minor Study sites: 52 to 53v18
- Minor Study sites: 51 to 52v17
- Minor Study sites: 50 to 51v15
- Notable Eligibility criteria expanded, about 20 words
- Study sites: 48 to 50
- Secondary endpoints: details revised at 6 of 8 entries
- Study title revised
- Minor Site details revised at 1 of 48 sitesv12
- Minor Study sites: 45 to 48v11
- Minor Study sites: 34 to 45v10
- Minor Study sites: 26 to 34
- Study completion date: Mar 31, 2029 to Mar 30, 2029
- Minor Study sites: 19 to 26v8
- Minor Study sites: 16 to 19v7
- Minor Study sites: 10 to 16v6
- Minor Study sites: 8 to 10v5
- Minor Study sites: 7 to 8v4
- Minor Study sites: 3 to 7
- Start date changed from estimate of Mar 31, 2025 to Mar 5, 2025
- Minor Study sites: 2 to 3
- Primary completion date: Mar 31, 2027 to Jan 31, 2027
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Participants with R/R aggressive B-cell Non-Hodgkin's Lymphoma will receive obinutuzumab pre-treatment, followed by glofitamab + gemcitabine + oxaliplatin, followed by glofitamab monotherapy. NOTE: Cohort A has been closed for recruitment.
Participants with R/R aggressive B-cell Non-Hodgkin's Lymphoma will receive obinutuzumab pre-treatment, followed by glofitamab monotherapy.
Drugs: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin
Sites
53 sites in 7 countries
United States 33, France 5, Italy 5, Germany 4, South Korea 3, Canada 2, Australia 1